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Introduction: Cartilage damage impacts on patient disability in rheumatoid arthritis (RA). The aims of this magnetic
resonance imaging (MRI) study were to investigate cartilage damage over three years and determine predictive factors.
Methods: A total of 38 RA patients and 22 controls were enrolled at t = 0 (2009). After 3 years, clinical and MRI data
were available in 28 patients and 15 controls. 3T MRI scans were scored for cartilage damage, bone erosion, synovitis
and osteitis. A model was developed to predict cartilage damage from baseline parameters.
Results: Inter-reader reliability for the Auckland MRI cartilage score (AMRICS) was high for status scores; intraclass
correlation coefficient (ICC), 0.90 (0.81 to 0.95) and moderate for change scores (ICC 0.58 (0.24 to 0.77)). AMRICS scores
correlated with the Outcome MEasures in Rheumatoid Arthritis Clinical Trials (OMERACT) MRI joint space narrowing (jsn)
and X-Ray (XR) jsn scores (r =0.96, P < 0.0001 and 0.80, P < 0.0001, respectively). AMRICS change scores were greater for
RA patients than controls (P = 0.06 and P = 0.04 for the two readers). Using linear regression, baseline MRI cartilage,
synovitis and osteitis scores predicted the three-year AMRICS (R2 = 0.67, 0.37 and 0.39, respectively). A multiple linear
regression model predicted the three-year AMRICS (R2 = 0.78). Baseline radial osteitis predicted increased cartilage scores
at the radiolunate and radioscaphoid joints, P = 0.0001 and 0.0012, respectively and synovitis at radioulnar, radiocarpal and
intercarpal-carpometacarpal joints also influenced three-year cartilage scores (P-values of 0.001, 0.04 and 0.01, respectively).
Conclusions: MRI cartilage damage progression is preceded by osteitis and synovitis but is most influenced by
pre-existing cartilage damage suggesting primacy of the cartilage damage pathway in certain patients.Introduction
The progression of structural damage in rheumatoid arth-
ritis (RA) is of great importance to rheumatologists and
patients alike as it is associated with the development of
joint deformity and eventually with disability [1]. Recent
work has suggested that cartilage damage, as reflected by
joint space narrowing (jsn), is more closely associated with
irreversible physical disability than bony erosion [2] and is,
therefore, a worthy focus of study, both to explore its use
as an outcome measure in clinical trials and to improve* Correspondence: f.mcqueen@auckland.ac.nz
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reproduction in any medium, provided the orour understanding of the pathological processes that drive
rheumatoid joint damage. The Sharp van der Heijde score
quantifies damage using two components, namely bone
erosion and jsn, and is the most commonly used outcome
measure in clinical trials [3]. Increasingly, magnetic reson-
ance imaging (MRI) scanning is taking the place of X-ray
(XR) for the assessment of RA as it is a more sensitive in-
strument for detecting bone erosion and has the added ad-
vantage of being able to image inflammatory change
within bone (osteitis) and synovium (synovitis), which are
the precursors of joint damage [4]. In recent years, the im-
aging of cartilage using high field MRI scanning and dedi-
cated cartilage-sensitive sequences has become feasible,
not only at large joints, such as the knee [5], but at the in-
formative small joints of the wrist where progressive cartil-
age loss can result in carpal collapse [6].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Trials (OMERACT) rheumatoid arthritis magnetic resonance
imaging score (RAMRIS) system [7] has been devised to
quantify inflammation and damage in rheumatoid joints and
is now being used in RA clinical trials [8,9]. When the RAM-
RIS was initially developed, MRI systems were not sophisti-
cated and quantification of the thin cartilage layer overlying
the carpal bones was found to be too unreliable for inclusion
in the score [10]. More recently, we devised the Auckland
MRI cartilage score (AMRICS) using 3T MRI technology and
found this to provide reliable cartilage quantification [11]
while the OMERACTgroup subsequently developed a similar
and also reproducible MRI jsn score [12]. Few studies to date
have examined cartilage change over time in rheumatoid
wrists, although Peterfy et al. have recently reported on the
Impact of Rituximab on Magnetic Resonance Imaging
Evidence of Synovitis and Bone Lesions in Patients With
Moderate or Severe Rheumatoid Arthritis (IMPRESS) trial
where patients received rituximab and/or methotrexate and
were scanned at zero, three and six months. They found that
the OMERACT MRI jsn score increased over this period,
mirroring the progression of erosive damage [8].
We have previously described a strong association be-
tween the finding of osteitis (MRI bone oedema) in RA pa-
tients at first presentation and subsequent radiographic jsn
and bone erosion six years later [13]. In light of these data,
we and others have suggested that damage to bone and car-
tilage may proceed from a bone-centred inflammatory focus
rather than according to the accepted paradigm which im-
plicates the inflamed synovium as the origin of pathology
[14,15]. In the current study, our aims have been to use high
field MRI scanning to extend our understanding of the pro-
cesses generating cartilage damage in RA. Using AMRICS,
we have examined cartilage damage progression over three
years in RA patients compared with controls. We have then
investigated for baseline clinical and MRI factors associated
with damage progression using a modelling approach.
Methods
Patients and clinical assessments
Patients and controls were recruited with the approval of the
New Zealand Multiregion Ethics Committee and all provided
written informed consent. A total of 38 RA patients, including
22 with early disease (onset within two years or less), 16 with
established RA and 22 healthy controls, were enrolled at t = 0
(2009). After three years, clinical and MRI data were available
in 28 RA patients (15 with early and 13 with established RA)
and 15 controls. RA patients were treated with standard
therapies including non-steroid anti-inflammatory drugs
(NSAIDs), conventional disease modifying anti-rheumatic
drugs (cDMARDs) and biological disease modifying anti-
rheumatic drugs (bDMARDs). At t = 3 years, disease activity
was low in the “early” RA group (median disease duration
4.5 years and Disease Activity Score 28 (DAS28) of 3.07),moderate in the “established” RA group (median disease dur-
ation 20 years and DAS28 of 3.56), and when the 2 RA
groups were combined the DAS28 was 3.42. Table 1 summa-
rises patient demographics, medications and disease activity.
MRI scans
3T MRI scans of the dominant wrist were scored for MRI
parameters of disease activity and joint damage, including
synovitis, osteitis, bone erosion and cartilage loss in RA pa-
tients and controls at baseline and after three years. MRI im-
ages were obtained on a 3T scanner Philips MR Systems
Achieve 3T, Koninklijke Philips Electronics NV, Eindhoven,
The Netherlands. An eight-element Philips SENSE 3.0T
Wrist Coil 8 Channel (Invivo Corp) Gainsville, Florida (re-
ceive only) was used. The dominant hand was placed in the
wrist coil where it fitted snugly by the patient’s side, palm fa-
cing the body, thumb anteriorly. The field of view was re-
stricted to the carpus, including the distal radioulnar joint
(dRUJ), extending to the metacarpal (MC) bases but exclud-
ing the metacarpophalangeal (MCP) joints. MRI scans were
performed using standard sequences appropriate for imaging
cartilage specifically as already described [11]. Briefly, these
included the following turbo spin echo sequences: T1
weighted (T1w) and T2 weighted (T2w) sequences with fat
saturation (FS) using spectral adiabatic inversion recovery
(SPAIR) in the axial and coronal planes and proton density
(PD) coronals (without FS) including an ultra-high resolution
sequence. T1wFS axial and coronal sequences were obtained
post-intravenous gadolinium diethylenetriamine pentaacetic
acid (GdDTPA) given at a standard dosage of 10 ml Omnis-
can (Gadodiamide; 5.0 mmol/10 ml or 2.87 g/10 ml; GE
Healthcare, Inc., Princeton, NJ, USA). In controls, scans were
performed without contrast for ethical reasons and no as-
sessment of MRI synovitis was attempted.
Scoring MRI scans for cartilage damage
Scoring of MRI scans was performed separately (blinded)
by the same two radiologists (AM and AC) who had scored
the original scans from t = 0, but without reference to these
scans, using a previously validated scoring system with car-
tilage sensitive sequences [11]. The AMRICS was developed
in 2010 and scores 0 to 4 for joint space narrowing at
each of eight joints within the carpus, including the distal
radio-ulnar, radiolunate, radioscaphoid, triquetrum-hamate,
capitate-lunate joint, scaphotrapezoid joint, second meta-
carpal base-trapezoid joint and third metacarpal base capi-
tate joints, giving a maximum possible total score of 32.
The system follows that developed by van der Heijde et al.
for radiographic joint space narrowing as follows: 0 (normal
thickness); 1 (asymmetrical or minimal narrowing to max-
imum of 25%); 2 (definite narrowing with loss of up to 50%
of the normal space); 3 (definite narrowing with loss of 50
to 99% of the normal space or subluxation) and 4 (absence
of joint space, presumed ankylosis or complete luxation).
Table 1 Demographics, medications and disease activity for RA patients and controls
Clinical features Early RA Late RA Healthy controls
(n = 15) (n = 13) (n = 15)
Age, yrs (median, range) 57 (36 to 87) 69 (43 to 84) 51 (37 to 62)
Female: male 11:4 8:5 13:2
Duration of RA, months 54 (48 to 72) 240 (83 to 456)
Ethnicity: Caucasian (%) 87 85 87
Anti-CCP antibody + VE (%) 93 92
RF positive (%) 60 69
Medications – No. (%)
NSAIDs 4 (27) 3 (23)
MTX alone* 3 1
cDMARD combinations**
MTX, SSZ, HCQ 0 2
MTX, HCQ, LEF 1 0
MTX, LEF 2 0
MTX, LEF, HCQ 0 1
MTX, LEF, SSZ 1 0
MTX, SSZ 0 2
MTX, HCQ 3 1
MTX, IM gold, LEF 0 1
HCQ, LEF 1 0
Prednisone 2.5 to 10 mg/d 4 (27) 2 (15)
bDMARDs*** 1 (7) 4 (31)
ETC 1 1
ADA 0 3
Disease activity (median, range)
Tender joint count (68) 8 (1 to 36) 17 (0 to 40)
Swollen joint count (66) 1 (0 to 6) 3 (0 to 8)
Pain VAS (mm) 14 (2 to 91) 20 (0 to 47)
Global VAS (mm) 2 (0 to 4) 2 (0 to 3)
HAQ score 0.75 (0 to 1.75) 0.88 (0 to 2.5)
PF SF - 36 65 (5 to 100) 65 (5 to 95)
CRP (mg/l) 2 (1 to 36) 4 (1 to 13) 1.2 (1 to 9)
DAS28CRP3v 3.1 (1.5 to 4.8) 3.6 (1.9 to 4.8)
ADA, adalimumab 40 mg fortnightly; anti-CCP, antibodies to cyclic citrullinated peptide; bDMARDs, biological disease modifying antirheumatic drugs; cDMARDs,
conventional disease modifying anti-rheumatic drugs; CRP, C-reactive protein; DAS28CRP3v, disease activity score 28, 3 variable CRP; HAQ, health assessment
questionnaire; HCQ, hydroxychloroquine 200 to 400 mg/day; IM gold, myocrisin 50 mg/month; LEF, leflunomide 10 to 20 mg/day; NSAIDs, nonsteroidal
anti-inflammatory drugs; PF SF-36, physical function component of short form-36 score; RF, rheumatoid factor; VAS, visual analogue scale.
*MTX, methotrexate 10 to 25 mg/week; **SSZ, sulphasalazine 1 to 3 g/day; ***ETC, etanercept 50 mg/week.
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Plain radiographs of the hands and feet were obtained in
28 RA patients and of the hands alone in 12 normal con-
trols. Radiographs were scored as pairs (known chrono-
logical order) by a rheumatologist (ND, Reader 3), blinded
to clinical and MRI data, for erosions and jsn using the
Sharp van der Heijde (SvdH) score [3].Statistical analysis
Inter-reader reliability for MRI cartilage change scores
(Auckland score) [11] was determined using absolute
agreement intraclass correlation coefficients (ICCs) for a
two-way random effects model. In addition, scans were
scored using the OMERACT jsn MRI score [12] and cor-
relations between the two scoring systems were examined
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lyses used data from Reader 1 (AM). T-test was used to
compare the change in cartilage score between RA and
controls. Pearson’s correlation coefficients were sought be-
tween MRI cartilage scores and radiographic jsn and total
SvdH scores. Clinical and MRI parameters were examined
to devise a model to predict cartilage damage after three
years using a multiple linear regression method. The in-
fluence of therapy was also examined in the model including
effects of methotrexate, methotrexate/sulphasalazine/hydro-
xychloroquine (triple therapy), anti-tumour necrosis factor
(anti-TNF) therapy and prednisone. Effects of anti-CCP and
rheumatoid factor positivity were also examined in the
model. Simple linear regression was used to determine
whether individual sites of cartilage loss were associated with
preceding inflammation in adjacent bones seen as MRI bone
oedema (osteitis) or joints (synovitis). The effects of anti-
CCP and RF status were also examined in this analysis.
Two-sided P-values less than 0.05 were used to determine stat-
istical significance and all confidence intervals were given at a
two-sided 95% level. All analyses were conducted using SAS
for Windows version 9.3. Foundation for MicrosoftW Win-
dowsW Copyright © 2012, SAS Institute Inc., Cary, NC, USA.
Results
Reliability of MRI cartilage scores and correlation with
OMERACT MRI jsn scores
Inter-reader reliability for cartilage scores was high with an
ICC of 0.9 (95% CI: 0.81 to 0.95). Inter-reader reliability for
cartilage change scores was moderate (ICC 0.58 (95% CI:
0.24 to 0.77)) using the difference between 2012 cartilage
scores and previous baseline cartilage scores in the database
(without re-reading scans in a paired fashion). Intra-reader
reliability was assessed at baseline and was 0.98 (95% CI:
0.96 to 1.00) for Reader 1 and 0.94 (95% CI: 0.87 to 1.00) for
Reader 2 [11]. At three years (2012), Auckland MRI cartilage
scores for both readers were highly correlated with OMER-
ACT cartilage scores (r = 0.94 for each). When the mean
Auckland MRI cartilage score was compared with the mean
OMERACTMRI jsn score the correlation was even stronger
(r = 0.96, P < .0001). Figure 1 shows this diagrammatically.
Change in MRI cartilage scores and XR jsn over time
MRI cartilage scores at t = 0 (2009) and t = 3 years (2012)
for all three groups are shown in Figure 2 (Reader 1 data).
When early and late RA groups were combined (N = 28),
there was a significant change in MRI cartilage score over
this period (mean change = 5 U, SE 0.93, Pr > |t| <0.0001).
MRI cartilage change scores were then analysed separately
for both readers and results are shown in Table 2. For
Reader 1 data, there was some evidence suggesting a
greater increase in cartilage scores in the RA group com-
pared with controls (P = 0.067) and for Reader 2 data, the
difference reached significance (P = 0.038). Changes in XRjsn scores in patients and controls (Reader 3) are also
shown in Table 2 and these were significantly different
(P = 0.04). At t = 3 years MRI cartilage scores were highly
correlated with XR jsn scores (r = 0.80, P <0.0001).
Baseline predictors of three-year cartilage and erosion
scores: simple linear regression analysis
We investigated whether the change in cartilage scores
over time for the RA group was associated with baseline
variables including clinical and MRI measures of disease
activity and damage, using simple and multiple linear re-
gression analyses. Results for simple linear regression are
shown in Table 3. The baseline MRI cartilage score was
the most significant determinant of the three-year cartil-
age score with strong positive relationship, (P <0.0001)
and this is graphically represented in Figure 3. The base-
line MRI erosion score was the most significant deter-
minant of the three-year erosion score (R2 = 0.87) and
also with strong positive relationship. All baseline (2009)
MRI scores were strongly correlated with each other, as
were three-year (2012) MRI scores and baseline score
(Additional file 1: Table S1).
A model to predict the three-year cartilage score; multiple
linear regression analysis
A model was devised using multiple linear regression
analysis, including clinical and MRI measures of disease
activity, to determine baseline factors associated with the
MRI cartilage score after three years. Table 4 shows the
optimal model which included the following baseline pa-
rameters: disease duration, age, sex, DAS28CRP, RF posi-
tivity, HAQ score and MRI cartilage score. The R2 of the
total model was 0.78, indicating that 78% of the variance
observed in the MRI cartilage score at three years was
explained by the model. The effect of substituting antici-
trullinated peptide antibody (ACPA) status for RF was to
slightly reduce the predictive power to 0.76. Without
ACPA or RF in the model, the R2 was 0.75. Because all
MRI scores at baseline were highly correlated, it was
only appropriate to include one score in the model and
the baseline cartilage score was chosen as this was the
most influential factor on univariate analysis (R2 = 0.67).
If the MRI bone oedema score was included instead, R2
for the total model was 0.65.
We then examined whether there was any effect from
medication on the model in terms of predicting progression
of cartilage damage. There was no significant effect from
any of the medication combinations (including triple ther-
apy, corticosteroid therapy and anti-TNF therapy) although
there were only small numbers of patients in each group
(N = 3, 6 and 5 patients, respectively, Table 1). When all
methotrexate/cDMARD combinations were examined as a
group, there was an effect on the model so that three-year
cartilage scores were on average 5.1 U higher in these
Figure 1 Auckland MRI cartilage score is highly correlated with OMERACT MRI jsn score (r = 0.96).
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to represent confounding by indication (more active
disease treated more intensively) as discussed below.
Figure 4 shows progression of MRI cartilage damage in
a patient maintained on methotrexate alone (intolerant
to other DMARDs).
Osteitis and synovitis predict cartilage score at
neighbouring joints after three years
Bone oedema/osteitis at the radius and lunate (separately
and summed) was investigated for associations with three-
year cartilage scores at the radiolunate joint. Similarly, os-
teitis at the radius and scaphoid (separately and summed)Figure 2 Progression of cartilage scores over three years in
controls and RA patients (Reader 1 data).was investigated for associations with three-year cartilage
scores at the radioscaphoid joint. Data are presented in
Table 5 and revealed a highly significant association for os-
teitis at the radius and the three-year radiolunate cartilage
score (P = 0.0001). Similarly, osteitis at the radius at base-
line was associated with the radioscaphoid cartilage score
after three years (P = 0.0012). When the effects of ACPA
or RF positivity were factored into this analysis, there was
no significant effect (data available on request). Figure 5
shows progression in cartilage thinning at the radiolunate
and radioscaphoid joints over the three-year period in a
patient who had prominent osteitis at the radius scored at
baseline. Similar to the findings for osteitis, we foundTable 2 MRI cartilage score and in XR jsn over three
years: RA vs controls
ΔAMRICS Reader 1
N Mean SE SD SRM Pr > |t|*
RA pts 28 5.00 0.93 4.92 1.02 0.0672
Controls 15 2.33 0.85 3.29 0.71
ΔAMRICS Reader 2
RA pts 28 4.21 0.79 4.17 1.01 0.038
Controls 15 1.73 0.56 2.19 0.79
ΔXR jsn Reader 3
RA pts 27 4.63 1.43 7.44 0.62 0.042
Controls 12 0.08 0.08 0.29 0.29
ΔAMRICS, change in Auckland MRI cartilage score from baseline (2009) to
three years (2012); ΔXR jsn, change in X-Ray joint space narrowing (Sharp van
der Heijde score, hands only) from baseline to three years; SD, standard
deviation; SE, standard error; SRM, standardised response mean.
*P-value for significance of difference between RA patients and controls.
Table 3 Simple linear regression analysis to determine
influence of baseline factors on damage outcomes
(RA patients)
Outcome = three-year MRI cartilage score
Parameter Estimate SE t Pr > |t| R2
RA duration (years) 0.04 0.01 4.38 0.0002 0.42
Sex F (ref = M) −1.67 3.26 −0.51 0.61 0.01
Age 0.13 0.11 1.22 0.23 0.05
DAS28CRP 2.39 1.52 1.57 0.1282 0.09
Anti-CCP positive 0.00 0.02 0.25 0.8056 0.00
HAQ 3.06 2.28 1.34 0.1913 0.06
MRI cartilage score 0.77 0.11 7.32 <.0001 0.67
MRI erosion score 0.52 0.11 4.77 <.0001 0.47
MRI bone oedema score 0.67 0.16 4.11 0.0004 0.39
MRI synovitis score 3.04 0.78 3.90 0.0006 0.37
Outcome = 3 year MRI erosion score
RA duration (years) 0.06 0.01 5.62 <.0001 0.55
Sex F (ref = M) -2.89 4.32 -0.67 0.50 0.02
Age 0.35 0.13 2.71 0.01 0.22
DAS28CRP 0.21 2.11 0.10 0.92 0.00
Anti-CCP positive -0.03 0.02 -1.41 0.17 0.07
HAQ 1.96 3.11 0.63 0.53 0.02
MRI cartilage score 0.88 0.18 4.98 <.0001 0.49
MRI erosion score 0.95 0.07 13.15 <.0001 0.87
MRI bone oedema score 1.20 0.15 7.98 <.0001 0.71
MRI synovitis score 5.34 0.78 6.85 <.0001 0.64
DAS28, Disease Activity Score 28; CCP, cyclic citrullinated peptide; CRP,
C-reactive protein; HAQ, health assessment questionnaire; RA, rheumatoid
arthritis.
Figure 3 Fit plot for Reader 1: baseline MRI cartilage scores
predicted three-year cartilage scores (P <0.0001).
Table 4 Multiple linear regression model predicting the
three-year MRI cartilage score*
Baseline parameters Estimate SE Pr > |t|
Disease duration (years) 0.01 0.01 0.2916
Sex F (ref = M) −3.10 2.08 0.1522
Age 0.02 0.07 0.7494
DAS28CRP 0.29 1.22 0.8127
RF 2.94 1.78 0.115
HAQ score 0.75 1.57 0.6379
MRI cartilage score 0.67 0.14 0.0001
*The R2 of the total model was 0.78, indicating 78% of the variance observed
in the MRI cartilage score at three years was explained by the model. DAS28,
Disease Activity Score 28; HAQ, health assessment questionnaire; RF,
rheumatoid factor.
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cartilage scores at neighbouring joints, three years later.
Synovitis scores at the three sites measured according to
the RAMRIS system in 2009 (radioulnar joint, radiocarpal
joint and intercarpal-carpometacarpal joints) were exam-
ined for an effect on the 2012 cartilage score at adjacent
joints. Again there was an association for each joint region
described above with P-values of 0.001, 0.04 and 0.01, re-
spectively. We also explored prediction of cartilage change
(ΔAMRICS) over three years from baseline parameters
but found no association for synovitis or osteitis, either
from sum scores (P = 0.52 and 0.63, respectively), or when
individual sites were examined separately (P =NS), data
not shown.
C-progressors and E-progressors
We examined our data to see whether there was any
support for the notion that patients favour one particular
damage pathway over the other, that is, that those who de-
velop erosions tend to erode further (E-progressors) while
those who damage cartilage continue preferentially in that
manner (C-progressors). Using multiple linear regression
with an outcome of cartilage damage at three years as al-
luded to above, the strongest predictor for the cartilage
score was the baseline cartilage score (R2 = 0.67). The
baseline MRI erosion score was also predictive but to a
lesser degree (R2 = 0.47). When the outcome of bone
erosion score was used, the strongest predictor was the
baseline erosion score (R2 = 0.87, P <0.0001), while the
baseline cartilage score was not quite as strongly pre-
dictive (R2 = 0.49, P = 0.01). These data would support
but do not prove the proposal above. Figure 6 shows
progression of cartilage and erosion scores for each pa-
tient from baseline to three years.
Discussion
This is the largest prospective MRI study of cartilage dam-
age in RA to be conducted outside of a clinical trial set-
ting, reflecting “real life” disease progression. The patients
Figure 4 Coronal proton density MRI wrist scans. A) Baseline MRI scan (2009) shows cartilage thinning at the radiolunate (score = 2 ) and
radioscaphoid joints (score = 1) (arrowheads) B) At 3 years (2012), the cartilage space narrowing has progressed; radiolunate score = 3 and radioscaphoid
joint score = 3 (arrowheads). A new erosion (white arrow) is also now seen to involve the triquetrum at the site of bone oedema at baseline.
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clinics and represent a typical spectrum of disease severity
and duration, on a variety of medications, including pre-
dominantly combination traditional DMARD therapy. A
relatively small number were taking bDMARDs, influ-
enced by the New Zealand government funding system
which only allows prescription of biological agents to pa-
tients with erosive RA who have failed multiple combina-
tions of traditional DMARDs. The first aim of the study
was to determine the operating characteristics of the
AMRICS in a longitudinal setting. We found this scoring
system performed well with high inter-reader reliability
for three-year status scores although reliability was only
moderate for cartilage change scores, probably influenced
by the fact that the three-year images were read separately
without reference to previous scans, which is a more strin-
gent test of scoring accuracy than reading paired images
in known chronological order [16]. The standardised re-
sponse means were high indicating good responsiveness of
the score for detecting cartilage change. This compares
with the findings of Haavardsholm et al. investigating MRI
and XR parameters for detecting structural change in
rheumatoid joints, where change in the RAMRIS erosionTable 5 Simple linear regression shows baseline bone
oedema predicts three-year cartilage score
Prediction of radiolunate cartilage score (2012)
Baseline bone oedema (2009) Estimate SE Pr >|t|
Distal radius 1.40 0.31 0.0001
Lunate 0.19 0.30 0.518
Sum score for distal radius and lunate 0.45 0.19 0.0247
Prediction of radioscaphoid cartilage score (2012)
Baseline bone oedema (2009) Estimate SE Pr >|t|
Distal radius 1.10 0.30 0.0012
Scaphoid 0.84 0.27 0.0045
Sum score distal radius and scaphoid 0.55 0.15 0.001score showed high sensitivity (SRM 0.89) as did the SvdH
total score (SRM 0.94) [17].
We found very strong correlations between the
AMRICS and the OMERACT MRI jsn score [12] for both
readers, and between AMRICS and the XR SvdH jsn score
[3], providing construct validity for the MRI cartilage score
[18]. We felt it important to include healthy controls,
some of whom may have osteoarthritis (OA) as a compari-
son group as some RA patients also have concomitant OA
that could affect cartilage thickness and have the potential
to progress over time. As we suspected, there was measur-
able cartilage damage progression in some controls. This
did affect RA-relevant sites such as the radiolunate and
radioscaphoid joints where cartilage thinning was ob-
served in several individuals related to degenerative joint
disease and also ulnar-lunate cartilage impaction, a not
uncommon finding in asymptomatic wrists [19]. Interest-
ingly, when RA and control groups were compared for
cartilage damage progression, only one reader found a sig-
nificant difference between them, while for the other
reader there was a statistical trend only (P = 0.06). The XR
jsn measure revealed very similar separation between pa-
tients and controls and just reached significance using a dif-
ferent reader. These data emphasise the importance of
including controls in any study of cartilage damage progres-
sion in RA and provide some indication of minimum group
size for future clinical trials. That MRI and XR produced
similar results for assessing cartilage damage progression
could be taken as an argument for using radiography alone
as an outcome measure. However, Peterfy et al. noted that
interposition of synovial tissue or joint effusion between
articular surfaces can decrease the accuracy of XR jsn mea-
surements implying that the direct measurement of cartil-
age thickness from MRI scans is advantageous [8]. A
further advantage of using MRI in assessing RA damage is
that it provides additional information about preceding os-
teitis and synovitis which may also impact upon manage-
ment decisions.
Figure 5 Marked progression of cartilage thinning is associated with high levels of osteitis at baseline. A) Coronal T2 FS image of the
wrist at baseline (2009) showing bone oedema at the scaphoid and radius with an early erosion at the ulnar aspect of the joint (lower circle). Florid
bone oedema is also seen involving the hamate (upper circle). B) Coronal PD ASY SENSE sequence showing asymmetrical reduction in radioscaphoid
cartilage (lower circle) and normal cartilage space at the triquetrum-hamate joint (upper circle). C) and D) show equivalent sequences from the same
patient after three years (2012) indicating that bone oedema has subsided but there has been marked progression in cartilage thinning at both
radioscaphoid and triquetrum-hamate joints.
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baseline predictors of three-year MRI cartilage scores. We
assessed measures of joint inflammation, including osteitis
and synovitis, as well as damage, including bone erosion
and cartilage thinning, individually and combined with
clinical scores to create a best-fit model to explain this
score. The best individual predictor was the baseline MRI
cartilage score. When all available baseline data were used
in a model, we were able to explain 76% of the variance
observed in the three-year cartilage score but 67% of this
was from the baseline cartilage score. These data indicate
that those patients who developed the most severe cartil-
age damage after three years were those who already had
significant damage at baseline. These findings are in agree-
ment with those of van der Heijde et al. studying radio-
graphic jsn in 870 joints from the ASPIRE trial [20]. They
found that for joints with jsn present, there was a prefer-
ence for worsening of jsn while for joints with evidence of
erosive damage, there was a preference for continuing ero-
sion. Thus, although both bone erosion and cartilage thin-
ning contribute to rheumatoid joint damage, these could
be separate processes that proceed via different patho-
logical pathways [21]. The effect of the RANKL inhibitor
denosumab in abrogating erosive progression without af-
fecting cartilage damage progression is given as further
evidence for this hypothesis [22].The modelling outcome described above indicates that
pre-existing cartilage damage can be used to predict a
worsening of that damage. Clearly this reflects the cohort
of patients studied who had established and sometimes
very longstanding disease. If inflammatory variables were
examined instead, baseline osteitis and synovitis were also
independent predictors of cartilage damage at three years
and on a site-by-site basis were highly likely to be associ-
ated with subsequent cartilage damage. This is consistent
with an inflammation-driven process leading to cartilage
damage. However, we were unable to predict the extent of
progression of cartilage change using these variables as,
for example, osteitis was very common adjacent to joints
that progressed as well as those that did not progress. This
may have been for one or more of the following reasons;
the AMRICS had relatively low sensitivity for detecting
cartilage change, joints were not examined over a suffi-
ciently long period for damage to become apparent, or be-
cause other factors, such as medication use, might have
influenced damage progression [23]. We did not factor in
the effect of tenosynovitis on cartilage damage as this fea-
ture was not scored on baseline or three-year scans in our
cohort. However, Navalho et al. [24] showed that MRI
tenosynovitis at the hands and wrists was predictive of
progression to criteria-positive RA in patients with very
early disease, and Lillegraven et al. [25] found that
Figure 6 MRI cartilage and erosion scores at baseline and three years: each patient as a bar.
McQueen et al. Arthritis Research & Therapy 2014, 16:R33 Page 9 of 11
http://arthritis-research.com/content/16/1/R33ultrasound-detected tenosynovitis of extensor carpi ulnaris
(ECU) was associated with progression in the RAMRIS ero-
sion score at the distal ulna over one year. Taken together,
these data suggest that a combination of synovitis, osteitis
and tenosynovitis could be a useful “total inflammation
score” to examine as a predictor of joint damage in future
studies.
We did examine for an effect of medication use in the
model, assuming that powerful anti-rheumatic agents
might slow progression of cartilage damage. We found no
effect from triple therapy, prednisone or anti-TNF agents,
possibly because of small numbers in each group. When
any combination of methotrexate-plus-cDMARDs was ex-
amined as a group, there was a significant effect on three-
year cartilage scores, which were on average 5.1 U higher
than for those not taking methotrexate/cDMARDs. This
finding is in the opposite direction to what would be ex-
pected if we were observing an effect of therapy on cartil-
age damage. It is therefore likely that we are observing a
“confounding by indication” effect as we reported in an
earlier cohort of RA patients followed prospectively for
the development of MRI erosions [26]. In that study, those
on DMARDs (including methotrexate) were more likely
to have erosive joint damage after one year, indicating that
more aggressive medication use tends to be instituted in
those with more active clinical disease.Conclusions
In summary, this study has answered some questions
relating to cartilage damage in RA and raised others.
We have confirmed that measuring progression of cartil-
age thinning over time is possible using MRI but our data
suggest that plain radiography could be comparable in
terms of separating patients from controls, when consider-
ing this endpoint alone. Longitudinal studies comparing
MRI with XR and CT scanning, are needed to further in-
vestigate this issue. However, we have shown that MRI
yields interesting information about inflammation preced-
ing cartilage damage and the strong associations between
baseline osteitis and synovitis and the three-year cartilage
score suggest that these measures could be important im-
aging biomarkers to indicate those at highest risk for car-
tilage damage progression. One of the most interesting
findings has been to support the notion that there are two
damage pathways; one that leads to erosion of bone and
one that leads to thinning of cartilage and that these seem
to be favoured by individual patients (E-progressors and
C-progressors, respectively). Further studies of the genetic
and immunopathogenic characteristics of these two
groups are warranted to improve our understanding of
factors leading to joint damage in RA and to determine
whether management strategies should be matched to the
tissue damage target.
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Additional file 1: Table S1. Correlations between MRI scores at
baseline and three years (Reader 1). Pearson’s correlation coefficients for
association between baseline MRI scores (2009) and three-year MRI scores
(2012) for Reader 1.
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